Several studies then demonstrated the superiority of tyrosine kinase inhibitors over first-line chemotherapy in terms of progression-free survival and quality of life in patients with advanced EGFR mutation-positive NSCLC (for review, see [17]). Here, EGFR is linked to non-small cell lung carcinoma.